ThermoGenesis Holdings Inc (THMO)
0.735
+0.08
(+13.08%)
USD |
NASDAQ |
Apr 25, 13:39
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 5.845M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -66.32% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.1917 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -4.593 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.99% |
Profile
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications. |
URL | https://www.thermogenesis.com |
Investor Relations URL | https://thermogenesis.com/investors/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | Aug. 12, 2021 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications. |
URL | https://www.thermogenesis.com |
Investor Relations URL | https://thermogenesis.com/investors/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | Aug. 12, 2021 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |